Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CSF1R over exp |
| Therapy | Cytarabine + Narazaciclib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R over exp | acute myeloid leukemia | sensitive | Cytarabine + Narazaciclib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of Narazaciclib (ON123300) and Cytosar-U (cytarabine) reduced tumor burden in a patient-derived xenograft (PDX) model of acute myeloid leukemia with CSF1R overexpression (PMID: 38641704). | 38641704 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38641704) | Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. | Full reference... |